PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Progenics Pharmaceuticals Inc's research and development for the three months ended in Dec. 2016 was USD 10.61 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2016 was USD 37.57 Mil.
This is the expense the company spent on research and development.
Progenics Pharmaceuticals Inc Research & Development for the trailing twelve months (TTM) ended in Dec. 2016 was 9.149 (Mar. 2016 ) + 7.988 (Jun. 2016 ) + 9.827 (Sep. 2016 ) + 10.605 (Dec. 2016 ) = USD 37.57 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Progenics Pharmaceuticals Inc Annual Data
|Research & Development||96.18||85.12||50.86||51.91||53.76||32.50||34.58||28.59||28.20||37.57|
Progenics Pharmaceuticals Inc Quarterly Data
|Research & Development||6.89||6.67||6.49||6.72||7.05||7.94||9.15||7.99||9.83||10.61|